Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature

K. Ghasemi Falavarjani; Q. D. Nguyen

doi:10.1038/eye.2013.107

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature

K. Ghasemi Falavarjani, Q. D. Nguyen

Research output: Contribution to journal › Review article › peer-review

344 Scopus citations

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

Original language	English (US)
Pages (from-to)	787-794
Number of pages	8
Journal	Eye (Basingstoke)
Volume	27
Issue number	7
DOIs	https://doi.org/10.1038/eye.2013.107
State	Published - May 31 2013
Externally published	Yes

Keywords

Aflibercept
Anti-vascular endothelial growth factor
Bevacizumab
Intravitreal injection
Ranibizumab
Safety

ASJC Scopus subject areas

Ophthalmology
Sensory Systems

Access to Document

10.1038/eye.2013.107

Cite this

@article{26213e288c74438eaa461aaca47f7fe3,

title = "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature",

abstract = "Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.",

keywords = "Aflibercept, Anti-vascular endothelial growth factor, Bevacizumab, Intravitreal injection, Ranibizumab, Safety",

author = "Falavarjani, {K. Ghasemi} and Nguyen, {Q. D.}",

note = "Funding Information: The University of Nebraska Medical Center, the employer of QDN, has received research funding from Genentech, Inc., Regeneron, Inc., and Abbott, Inc,. QDN has served on the Steering Committee for clinical trials sponsored by Genentech, Inc. and Regeneron, Inc. QDN has served on the Scientific Advisory Boards for Santen, Inc. and Bausch and Lomb, Inc. KGF has no conflict of interest.",

year = "2013",

month = may,

day = "31",

doi = "10.1038/eye.2013.107",

language = "English (US)",

volume = "27",

pages = "787--794",

journal = "Eye (Basingstoke)",

issn = "0950-222X",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Adverse events and complications associated with intravitreal injection of anti-VEGF agents

T2 - A review of literature

AU - Falavarjani, K. Ghasemi

AU - Nguyen, Q. D.

N1 - Funding Information: The University of Nebraska Medical Center, the employer of QDN, has received research funding from Genentech, Inc., Regeneron, Inc., and Abbott, Inc,. QDN has served on the Steering Committee for clinical trials sponsored by Genentech, Inc. and Regeneron, Inc. QDN has served on the Scientific Advisory Boards for Santen, Inc. and Bausch and Lomb, Inc. KGF has no conflict of interest.

PY - 2013/5/31

Y1 - 2013/5/31

N2 - Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

AB - Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

KW - Aflibercept

KW - Anti-vascular endothelial growth factor

KW - Bevacizumab

KW - Intravitreal injection

KW - Ranibizumab

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84880268774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880268774&partnerID=8YFLogxK

U2 - 10.1038/eye.2013.107

DO - 10.1038/eye.2013.107

M3 - Review article

C2 - 23722722

AN - SCOPUS:84880268774

SN - 0950-222X

VL - 27

SP - 787

EP - 794

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

IS - 7

ER -

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this